RxDoctor Payments Data

Matthew Miller, MD

Glaucoma Specialist · Colorado Springs, CONPI 1861804825

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Alcon at 28.7% of the total.

$1,443in general payments, 2019–2025

Across 41 payments — averaging $35.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$414
  • AbbVie$304
  • Bausch & Lomb Americas Inc.$201
  • Rxsight Inc$155
  • Sight Sciences, Inc.$147
  • NEW World Medical,inc.$105
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$1,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$428,748
Medicare patients
1,059
Services billed
3,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost110$66,835
RhopressaNetarsudil Mesylate84$38,073
LumiganBimatoprost41$21,127
RestasisCyclosporine23$20,768
CombiganBrimonidine Tartrate/Timolol32$15,800
Prednisolone Acetate481$15,716
Latanoprost1,350$15,074
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat678$12,736
TafluprostTafluprost/Pf31$10,999
VyzultaLatanoprostene Bunod12$9,119
Brimonidine Tartrate598$8,638
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol60$8,441
Alphagan PBrimonidine Tartrate16$7,128
Dorzolamide-TimololDorzolamide/Timolol/Pf43$6,776
Travoprost29$5,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$14$104,908194 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$304$64,824112 claims
Bausch & Lomb Americas Inc.Vyzulta$201$9,11912 claims
AlconSimbrinza$414$3,32914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →